MedImmune Inc. deal

MEDI (Gaithersburg, Md.) acquired worldwide exclusive rights to commercialize T10B9, an anti-T cell murine monoclonal antibody developed at the University of Kentucky.

In a 76-patient, blinded, Phase II trial of T10B9 compared with Orthoclone OKT3, the only commercially available Mab to treat graft rejection in kidney transplant patients, T10B9 demonstrated long-term graft survival of 87 percent vs. 79 percent for patients receiving OKT3 (p<0.55). Within 48 hours of the initiation of treatment, kidney function was significantly improved in patients receiving T10B9 compared with those receiving OKT3 (p<0.001). Cytokine levels were significantly less elevated with T10B9 compared with OKT3 (p<0.005) and side effects were observed significantly less frequently. ...